Search Results - "Marinello, A."

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer by McDaid, W. J., Wilson, L., Adderley, H., Martinez-Lopez, A., Baker, M. J., Searle, J., Ginn, L., Budden, T., Aldea, M., Marinello, A., Aredo, J. V., Viros, A., Besse, B., Wakelee, H. A., Blackhall, F., Castillo-Lluva, S., Lindsay, C. R., Malliri, A.

“…Abstract Introduction KRAS G12C and KRAS G12D inhibitors represent a major translational breakthrough for non-small cell lung cancer (NSCLC) and cancer in…”
Get full text

The Effect of Joint Hypermobility Syndrome on DOMS and Recovery Time by Ostuni, Nicole F, Marinello, Charles A, Luzhnyy, Taras, Pawlikowski, Alexa, Vlasaty, Connor, Thomatos, Georgios, Douris, Peter C

“…Previous research has reported that people with Joint Hypermobility Syndrome (JHS) and Ehlers-Danlos Syndrome (EDS) generally experience a high rate of…”
Get full text

Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer by De Sanctis, R., D'Antonio, F., Agostinetto, E., Marinello, A., Masci, G., Zuradelli, M., Losurdo, A., Guiducci, D., Tinterri, C., Testori, A., Gatzemeier, W., Errico, V., Torrisi, R., Santoro, A.

Get full text

2253P RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer by Adderley, H., McDaid, W., Searle, J., Wilson, L., Marinello, A., Aldea, M., Aredo, J., Wakelee, H., Besse, B., Malliri, A., Lindsay, C.R.

Get full text

113 (PB101): Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer by Adderley, H., McDaid, W., Woodhouse, L., Carter, M., Aldea, M., Marinello, A., Seamon, K., Holderfield, M., Singh, M., Smith, J., Aredo, J., Besse, B., Wakelee, H., Blackhall, F., Wedge, D., Malliri, A., Lindsay, C.

Get full text

2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC by Marinello, A., Ghigna, M.R., F.G. Dall'Olio, Mandarano, M., Russo, A., Raimbourg, J., Terrisse, S., Metro, G., Gazzah, A., Barlesi, F., Remon Masip, J., Planchard, D., Besse, B., Aldea, M.

Get full text

2339P Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC by F.G. dall'Olio, Vasseur, D., Mamann, A., Garcia, C.A., Beshiri, K., Marinello, A., Tagliamento, M., Ghigna, M.R., Aldea, M., Planchard, D., Pasquina, L., Barlesi, F., Italiano, A., Madison, R., Oxnard, G., Besse, B.

Get full text

34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions by Marinello, A., Duruisseaux, M., Zrafi, W.S., Dall'Olio, F.G., Massa, G., Iranzo, P., Tabbò, F., Guisier, F., Lindsay, C., Fallet, V., Audigier-Valette, C., Mezquita, L., Calles, A., Mountzios, G., Tagliamento, M., Raimbourg, J., Terrisse, S., Planchard, D., Besse, B., Aldea, M.

Get full text

1334P Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency by Grecea, A.M., Ghigna, M.R., Marinello, A., Remon Masip, J., Vasseur, D., Meyer, M-L., Soldato, D., Lavaud, P., Gazzah, A., Abdayem, P., Frelaut, M., Kasraoui, I., Garcia, C.A., Botticella, A., Levy, A., Scoazec, J-Y., Barlesi, F., Planchard, D., Besse, B., Aldea, M.

Get full text

Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer by Tagliamento, M., Aldea, M., Verge, V., Bayle, A., Blanc-Durand, F., Marinello, A., Hadoux, J., Loriot, Y., Vasseur, D., Nicotra, C., Smolenschi, C., Martin-Romano, P., Hollebecque, A., Ponce, S., Lacroix, L., Rouleau, E., Marzac, C., Italiano, A., Besse, B., Micol, J.B.

Get full text

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario by Dipasquale, Angelo, Marinello, Arianna, Santoro, Armando

“…Hepatocellular carcinoma (HCC) is the fifth most common malignancy across the world. Alongside improvement in local approaches for early stages, the prognosis…”
Get full text

Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions by Marinello, A., Vasseur, D., Conci, N., Lindsay, C., Metro, G., Ferrara, R., Eisert, A., Citarella, F., Fallet, V., Audugier-Valette, C., Cousin, S., Tabbò, F., Russo, A., Calles Blanco, A., Iranzo Gomez, P., Tagliamento, M., Mezquita, L., Ponce, S., Besse, B., Aldea, M.

Get full text

1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC by Marinello, A., Vasseur, D., Conci, N., Fallet, V., Audigier-Valette, C., Cousin, S., Tabbò, F., Guisier, F., Russo, A., Calles Blanco, A., Metro, G., Massa, G., Citarella, F., Eisert, A.K., Iranzo Gomez, P., Tagliamento, M., Mezquita, L., Lindsay, C., Ponce, S., Aldea, M.

Get full text

Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study by Henrotin, Yves, Bannuru, Raveendhara, Malaise, Michel, Ea, Hang-Korng, Confavreux, Cyrille, Bentin, Jacques, Urbin-Choffray, Didier, Conrozier, Thierry, Brasseur, Jean-Pierre, Thomas, Philippe, Hick, Anne-Christine, Marinello, Alessandro, Giordan, Nicola, Richette, Pascal

“…The objective of this pilot study was to identify biological, clinical or structural biomarkers of an intra-articular hyaluronic acid injection efficacy…”
Get full text

221PReal-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer by De Sanctis, R, D'Antonio, F, Agostinetto, E, Marinello, A, Masci, G, Zuradelli, M, Losurdo, A, Guiducci, D, Tinterri, C, Testori, A, Gatzemeier, W, Errico, V, Torrisi, R, Santoro, A

Get full text

242P Prognostic role of tumor microenvironment features in advanced non-small cell lung cancer molecular subtypes: A multicentric, retrospective study by Zullo, L., Marinello, A., Ghigna, M.R., De Maglio, G., Citarella, F., Pagliaro, A., Gazzah, A., Lavaud, P., Abdayem, P., Frelaut, M., Parisi, C., Masip, J. Remon, Barlesi, F., Scoazec, J-Y., Besse, B., Planchard, D., Aldea, M.

Get full text

80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC) by Zullo, L., Ghigna, M.R., Zrafi, W.S., Marinello, A., Vasseur, D., Frelaut, M., Abdayem, P., Tagliamento, M., Lavaud, P., Gazzah, A., Friboulet, L., Scoazec, J-Y., Remon, J., Barlesi, F., Besse, B., Planchard, D., Aldea, M.

Get full text

Hyaluronan derivative Hymovis® increases cartilage volume and type II collagen turnover in osteoarhritic knee: data from Mokha study by Henrotin, Y., Bannuru, R., Malaise, M., Ea, H.-K., Confavreux, C., Bentin, J., Urbin-Choffray, D., Conrozier, T., Brasseur, J.-P., Thomas, P., Marinello, A., Giordan, N., Richette, P.

Get full text

Activity and Safety of Trabectedin in patients with Sarcomatoid / Biphasic Malignant Pleural Mesothelioma (MPM) by Cortinovis, D., Hollander, L., Floriani, I., Grosso, F., Marinello, A., Ceresoli, G.L., Pacchetti, I., Zucali, P.A., Tiseo, M., D'Incalci, M., Canova, S., Ugo, F., Vukcaj, S., Abbate, M.I., Zai, S., Bidoli, P.

Get full text

Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450 by Marinello, A J, Bansal, S K, Paul, B, Koser, P L, Love, J, Struck, R F, Gurtoo, H L

“…The hepatic cytochrome P-450-mediated metabolism and metabolic activation of [chloroethyl-3H]cyclophosphamide [( chloroethyl-3H]CP) and [4-14C]cyclophosphamide…”
Get full text